MannKind Corporation
NASDAQ:MNKDBiotechnology
-$0.02 today
- Market cap
- $1.31B
- Beta
- 1.11
- P/E (TTM)
- -50.3
- EPS (TTM)
- -$0.08
Volume 2.12M
Average 5.73M
MNKD Total Current Assets
All assets expected to be converted to cash or used up within one year.
MannKind CorporationNASDAQ: MNKD
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 8.2% from a year ago
Total current assets stood at $251.16M at the end of Q1 FY2026, down 8.2% from a year earlier and down 13.9% from the prior quarter. Over 3 fiscal years it compounded at +7.5% a year.
Context
- Total current assets amounted to 33.7% of total assets at the end of Q1 FY2026, down 33.0 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -8.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 291.58M USD
- Year-over-year change
- +8.7%
- 4-year CAGR
- +7.4%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 291.58M | +8.7% |
| FY2024 | 2024-12-31 | 268.31M | -28.1% |
| FY2023 | 2023-12-31 | 373.39M | +59.0% |
| FY2022 | 2022-12-31 | 234.9M | +7.0% |
| FY2021 | 2021-12-31 | 219.49M | — |
Total Current Assets vs competitors
How MNKD compares with its peers on the latest reported figures
- MNKD's Mar 2026 total current assets of $251.16M is the 3rd highest of the 6 companies compared; the peer median is $245.24M.
- Its year-over-year change of -8.2% is the 4th highest of 6, against a peer median of +1.4%.
- Total current assets amounts to 33.7% of total assets for MNKD, versus a peer median of 64.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $417.63M | +177.9% | +5.8% | 88.4% | |
| Mar 2026 | $251.68M | +53.9% | +8.8% | 64.2% | |
| Mar 2026 | $251.16M | -8.2% | +7.5% | 33.7% | |
SPRYARS Pharmaceuticals, Inc. | Mar 2026 | $245.24M | -19.3% | +0.9% | 85.3% |
| Mar 2026 | $68.15M | -48.2% | -5.3% | 25.3% | |
| Mar 2026 | $7.36M | +1.4% | -29.9% | 61.8% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding MNKD) | $245.24M | +1.4% | +0.9% | 64.2% | |
Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 124.18M | 69.77M | 238.48M | 46.34M | 74.88M |
| Short-term Investments | 79.93M | 101.08M | 56.62M | 150.92M | 96.46M |
| Net Receivables | 4.74M | 16.8M | 14.9M | 11.8M | 38.37M |
| Inventory | 7.15M | 21.77M | 28.55M | 27.89M | 35.31M |
| Other Current Assets | 0 | 25.48M | 34.85M | 31.36M | 46.55M |
| Total Current Assets | 219.49M | 234.9M | 373.39M | 268.31M | 291.58M |
| Property, Plant & Equipment (Net) | 36.61M | 45.13M | 84.22M | 85.37M | 82.42M |
| Goodwill | 0 | 2.43M | 1.93M | 1.93M | 67.6M |
| Intangible Assets | 0 | 1.15M | 1.07M | 5.27M | 5.07M |
| Long-term Investments | 56.62M | 1.96M | 7.16M | 5.48M | 5.01M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8.44M | 9.72M | 7.43M | 27.49M | 340.5M |
| Total Non-current Assets | 101.67M | 60.39M | 101.81M | 125.54M | 500.6M |
| Total Assets | 321.16M | 295.28M | 475.2M | 393.84M | 792.18M |
| Account Payables | 6.96M | 11.05M | 9.58M | 6.79M | 9.03M |
| Short-term Debt | 6.98M | 9.57M | 20M | 0 | 49.24M |
| Tax Payables | 0 | 0 | 1.56M | 49K | 0 |
| Deferred Revenue | 827K | 1.73M | 9.09M | 12.41M | 15.33M |
| Other Current Liabilities | 9.53M | 16.43M | 30.97M | 30.37M | 69.78M |
| Total Current Liabilities | 48.35M | 67.3M | 104.13M | 81.84M | 171.03M |
| Long-term Debt | 281.2M | 273.49M | 248.7M | 36.05M | 320.36M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 24.49M | 37.68M | 69.79M | 51.16M | 39.98M |
| Other Non-current Liabilities | 175.43M | 162.01M | 294.82M | 291.97M | 208.05M |
| Total Non-current Liabilities | 482.16M | 478.52M | 617.24M | 390.82M | 672.17M |
| Total Liabilities | 530.51M | 545.82M | 721.37M | 472.66M | 843.2M |
| Common Stock | 2.52M | 2.64M | 2.7M | 3.03M | 3.08M |
| Retained Earnings | (3.13B) | (3.22B) | (3.23B) | (3.2B) | (3.2B) |
| Accumulated OCI | 0 | 0 | 0 | 1.11M | 115K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (209.35M) | (250.54M) | (246.17M) | (78.82M) | (51.02M) |
| Total Debt | 289.22M | 288.4M | 272.62M | 47.7M | 473.38M |
| Net Debt | 165.04M | 218.63M | 34.14M | 1.36M | 398.5M |
MannKind Corporation
NASDAQ:MNKD
Intrinsic Alpha fair value
Locked
Current Price
$4.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.